Nail pigmentation induced by chemotherapy: an observational study of patients with early-stage breast cancer

• DOI: 10.1007/s44178-022-00008-7
• Publication Date: 2022-07-05T18:07:28Z
• Authors: Kuikui Jiang; Simei Shi; Qiulian Lin; Peng Sun; Luan Zhang; Zhongyu Yuan; Ruoxi Hong; Yanxia Shi; Xia Liu; Jingmin Zhang; Jiajia Huang; Xiwen Bi; Wen Xia; Qianyi Lu; Qiufan Zheng; Shusen Wang; Fei Xu
• Keywords: Onycholysis

Abstract Purpose Chemotherapy-induced nail pigmentation is a common adverse effect, but prospective studies focussing on its onset, recovery, and severity are few. We aim to evaluate the pattern of chemotherapy-induced in early-stage breast cancer patients by calculating comprehensive score based hyperpigmentation area color depth plate. Methods This prospective, observational study was conducted between February 2019 December 2019. Early-stage scheduled receive anthracyclines combined with cyclophosphamide or taxane-containing regimens were enrolled. The clinicopathologic characteristics treatment protocols collected. patterns, duration changes photographed recorded regularly. Results A total 90 most change ( n = 81, 90.0%), followed onycholysis 39, 43.3%), Beau’s lines 19, 21.1%), Mees’ 16, 17.8%), Muehrcke’s 7, 7.8%), hemorrhage 1, 1.1%). Forty-four (48.9%) developed severe pigmentation. median onset time 37 days after initiation chemotherapy. At latest follow-up, 55(67.9%) achieved remission melanonychia recovery 118 days. 214 Conclusion Our revealed specific pigmentation, which onsets early recovers slowly high incidence patients. results provide reference for further intervention studies. Trial Registration ClinicalTrials.gov Identifier: NCT04215744 . Registered 30 2019—Retrospectively registered.